A unique study from Copenhagen, investigating the prognostic value of plasma YKL-40 in platinum-resistant ovarian cancer patients treated with bevacizumab found that elevated YKL-40 levels (>95th percentile) at baseline were associated with poor survial and residual disease after primary surgery(6). Here, CHI3L1 is linked to ovarian cancer.